Joint initiative of 5 EU countries calls for 'unified approach' to pharma framework amid US drug pricing pressure

Fierce Pharma· June 13, 2026

Five European Union member states have launched a joint initiative calling for a unified approach to the region's pharmaceutical framework. This move comes as European regulators face increasing pressure related to drug pricing and competition from the United States market. The coalition seeks to harmonize policies to ensure the sustainability of healthcare systems while maintaining the region's attractiveness for pharmaceutical innovation.

Read the full story at Fierce Pharma

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Fierce Pharma.

More in Pharmaceutical

India pharma’s growth markets

McKinsey & Company has published an analysis regarding the growth markets within India's pharmaceutical industry. The report explores the strategic opportunities available for companies operating in this region as the market continues to mature and expand. This information is vital for pharmaceutical stakeholders seeking to align their long-term growth strategies with emerging trends in one of the world's most significant drug manufacturing and consumption hubs.

June 14, 2026

World Erythropoietin Formulation

The global erythropoietin (EPO) formulation market is undergoing a structural transformation as it enters 2026, driven by significant biosimilar penetration and shifting demand fundamentals. While chronic kidney disease (CKD) anemia remains the primary market anchor accounting for up to 75% of consumption, the sector is facing a 3-5% annual value decline in mature markets due to biosimilar-driven price compression. This shift is critical for the pharmaceutical industry as it necessitates a move toward high-concentration formulations and more disciplined procurement strategies across a regionally diversified supply architecture.

June 14, 2026

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

The rapid growth of the GLP-1 obesity drug market is attracting significant investor interest, leading to the identification of specific exchange-traded funds (ETFs) focused on the sector. As pharmaceutical giants expand their metabolic health portfolios, financial analysts are tracking the impact of these high-demand therapies on broader healthcare indices. This boom reflects a major shift in pharmaceutical market priorities toward chronic weight management solutions.

June 13, 2026

UK approves Novo weight-loss pill to edge open European market

The United Kingdom has granted approval for a new weight-loss pill developed by Novo Nordisk, marking a significant step in the company's expansion within the European market. This regulatory milestone addresses the growing demand for obesity treatments and provides a non-injectable option for patients. The approval is expected to influence the competitive landscape for metabolic health therapies across the region.

June 13, 2026